Prophylaxis in haemophilia with inhibitors: update from international experience-Reference-Cited by-同舟云学术

Prophylaxis in haemophilia with inhibitors: update from international experience

Published:2010-03 Issue: Volume:16 Page:16-23
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

CARCAO M.,LAMBERT T.

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2009.02198.x/fullpdf

Reference39 articles.

1. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma;Livnat;Haemophilia,2008

2. European study on orthopaedic status of haemophilia patients with inhibitors;Morfini;Haemophilia,2007

3. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease;Hilgartner;Haemophilia,2003

4. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference;Berntorp;Haemophilia,2006

5. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors;Tjønnfjord;Vasc Health Risk Manag,2007

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

2. The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients;TH Open;2022-10

3. Management of Acute Hemarthrosis in Hemophilia (Including Joint Aspiration);Advances in Hemophilia Treatment;2022

4. Transperitoneal hernioplasty in a patient with severe hemophilia A on preventive treatment with emicizumab;Pediatric Hematology/Oncology and Immunopathology;2021-10-08

5. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study;The Lancet Haematology;2019-06